lunes, 13 de mayo de 2013

VIH vacunarse "a lo pobre" / Merck & GSK de rebajas...

Merck & Co. (MRK) and GlaxoSmithKline Plc (GSK) will cut the prices of their cervical cancer vaccines for some countries in the first large-scale effort to get the shots to millions of girls in the world’s poorest regions. 

 The companies will sell their vaccines to eligible low-income countries for about $4.50 a dose, a more than 95 percent discount from the prices charged in the U.S., said Nina Schwalbe, managing director for policy and performance at the GAVI Alliance, which will purchase the vaccines and distribute them to the countries at a further reduced price. (Más)
Publicar un comentario